论文部分内容阅读
目的研究硼替佐米、沙利度胺联合常规化疗对新发骨髓瘤患者肾功能的影响。方法 85例患者随机分为观察组(55例)与对照组(30例),观察组给予常规化疗联合硼替佐米、沙利度胺治疗,对照组给予单一常规治疗,比较两组肾功能改善及病情缓解情况。结果观察组肾功能好转、肾功能逆转率分别为56.36%、21.81%高于对照组的36.67%、13.33%,但差异无统计学意义(P>0.05),观察组总有效率78.18%显著高于对照组的50.00%,差异有统计学意义(P<0.05);观察组总体有效率81.82%与对照组的53.33%比较,差异有统计学意义(P<0.05)。结论常规化疗联合硼替佐米、沙利度胺治疗新发骨髓瘤效果显著,可改善患者肾功能,具有较高的临床应用价值。
Objective To study the effects of bortezomib and thalidomide combined with conventional chemotherapy on renal function in patients with newly diagnosed myeloma. Methods A total of 85 patients were randomly divided into observation group (55 cases) and control group (30 cases). The observation group was given conventional chemotherapy combined with bortezomib and thalidomide, while the control group was given a single routine treatment. The renal function was improved And the condition of relief. Results The improvement of renal function and renal function reversal rate in the observation group were 56.36% and 21.81% respectively, which was 36.67% and 13.33% higher than that in the control group, but the difference was not statistically significant (P> 0.05). The total effective rate was 78.18% (P <0.05). The total effective rate was 81.82% in the observation group compared with 53.33% in the control group, the difference was statistically significant (P <0.05). Conclusion Conventional chemotherapy combined with bortezomib and thalidomide has a significant effect on the treatment of new-onset myeloma, which can improve renal function and has high clinical value.